ANNEXON, INC. Debt Securities, Available-for-sale, Amortized Cost
ANNEXON, INC. (ANNX) had Debt Securities, Available-for-sale, Amortized Cost of $195.75 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $195.75M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $214.06M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $236.28M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $179.40M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $195.75M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $214.06M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $236.28M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $179.40M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $218.46M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $250.96M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $309.27M 10-K · filed 2026-03-30 |
| 2024-09-30 | $330.01M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $365.77M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $253.51M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $251.22M 10-K · filed 2025-03-03 |
| 2023-09-30 | $164.30M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $192.46M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $227.73M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $242.36M 10-K · filed 2024-03-26 |
| 2022-09-30 | $269.27M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $177.29M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $206.37M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $242.08M 10-K · filed 2023-03-06 |
| 2021-09-30 | $270.78M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $301.79M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $326.07M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $350.62M 10-K · filed 2022-03-01 |
| 2019-12-31 | $43.62M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |